These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28326336)

  • 1. Association between gastrointestinal events and compliance with osteoporosis therapy.
    Siris ES; Fan CS; Yang X; Sajjan S; Sen SS; Modi A
    Bone Rep; 2016 Jun; 4():5-10. PubMed ID: 28326336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship Between Gastrointestinal Events and Compliance With Osteoporosis Therapy: An Administrative Claims Analysis of the US Managed Care Population.
    Modi A; Sajjan S; Michael Lewiecki E; Harris ST; Papadopoulos Weaver J
    Clin Ther; 2016 May; 38(5):1074-80. PubMed ID: 27112533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of gastrointestinal events with osteoporosis treatment initiation and treatment compliance in Germany: An observational study.
    Modi A; Fan CS; Tang J; Weaver JP; Sajjan S
    Bone Rep; 2016 Dec; 5():208-213. PubMed ID: 28580388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal Events Among Patients Initiating Osteoporosis Therapy: A Retrospective Administrative Claims Database Analysis.
    Modi A; Siris ES; Steve Fan CP; Sajjan S
    Clin Ther; 2015 Jun; 37(6):1228-34. PubMed ID: 25866298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of gastrointestinal events and osteoporosis treatment initiation in newly diagnosed osteoporotic Israeli women.
    Yu J; Goldshtein I; Shalev V; Chodick G; Ish-Shalom S; Sharon O; Modi A
    Int J Clin Pract; 2015 Sep; 69(9):1007-14. PubMed ID: 26278464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between gastrointestinal events and osteoporosis treatment initiation in women diagnosed with osteoporosis in France: a retrospective analysis.
    Cortet B; Modi A; Tang J; Fan CP; Sajjan S; Weaver JP
    BMC Musculoskelet Disord; 2016 Apr; 17():195. PubMed ID: 27139225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Undertreatment of osteoporosis and the role of gastrointestinal events among elderly osteoporotic women with Medicare Part D drug coverage.
    Siris ES; Yu J; Bognar K; DeKoven M; Shrestha A; Romley JA; Modi A
    Clin Interv Aging; 2015; 10():1813-24. PubMed ID: 26604724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal events and association with initiation of treatment for osteoporosis.
    Modi A; Siris ES; Tang J; Sajjan S; Sen SS
    Clinicoecon Outcomes Res; 2015; 7():603-13. PubMed ID: 26648746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of GI events on persistence and adherence to osteoporosis treatment: 3-, 6-, and 12-month findings in the MUSIC-OS study.
    Modi A; Sen S; Adachi JD; Adami S; Cortet B; Cooper AL; Geusens P; Mellström D; Weaver JP; van den Bergh JP; Keown P; Sajjan S
    Osteoporos Int; 2018 Feb; 29(2):329-337. PubMed ID: 29110061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoporotic fracture rate among women with at least 1 year of adherence to osteoporosis treatment.
    Modi A; Tang J; Sen S; Díez-Pérez A
    Curr Med Res Opin; 2015 Apr; 31(4):767-77. PubMed ID: 25708648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy.
    Modi A; Siris ES; Tang J; Sen S
    Curr Med Res Opin; 2015 Apr; 31(4):757-65. PubMed ID: 25661017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Gastrointestinal Events and Health Care Resource Utilization Among Patients with Osteoporosis: Analysis of a U.S. Managed Care Population.
    Modi A; Gold DT; Yang X; Fan CP; Sajjan SG
    J Manag Care Spec Pharm; 2015 Sep; 21(9):811-21. PubMed ID: 26308228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France.
    Cramer JA; Lynch NO; Gaudin AF; Walker M; Cowell W
    Clin Ther; 2006 Oct; 28(10):1686-94. PubMed ID: 17157124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis.
    Penning-van Beest FJ; Erkens JA; Olson M; Herings RM
    Curr Med Res Opin; 2008 May; 24(5):1337-44. PubMed ID: 18380910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost and health care resource use associated with noncompliance with oral bisphosphonate therapy: an analysis using Danish health registries.
    Kjellberg J; Jorgensen AD; Vestergaard P; Ibsen R; Gerstoft F; Modi A
    Osteoporos Int; 2016 Dec; 27(12):3535-3541. PubMed ID: 27394414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Dosing Interval on Compliance of Osteoporosis Patients on Bisphosphonate Therapy: Observational Study Using Nationwide Insurance Claims Data.
    Lee H; Lee S; Kim D; Cho W; Cho S; Yoon S; Lee S
    J Clin Med; 2021 Sep; 10(19):. PubMed ID: 34640368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
    Cramer JA; Amonkar MM; Hebborn A; Altman R
    Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective evaluation of persistence in osteoporosis therapy with oral bisphosphonates in Italy: the TOBI study.
    Gonnelli S; Caffarelli C; Letizia Mauro G; Di Munno O; Malavolta N; Migliaccio S; Nuti R
    Aging Clin Exp Res; 2019 Nov; 31(11):1541-1547. PubMed ID: 31030419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of treatment benefit due to low compliance with bisphosphonate therapy.
    Penning-van Beest FJ; Erkens JA; Olson M; Herings RM
    Osteoporos Int; 2008 Apr; 19(4):511-7. PubMed ID: 17874028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of persistence and compliance with bisphosphonates for osteoporosis.
    Cramer JA; Gold DT; Silverman SL; Lewiecki EM
    Osteoporos Int; 2007 Aug; 18(8):1023-31. PubMed ID: 17308956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.